BeOne Medicines (NASDAQ:ONC) reported Phase 3 HERIZON-GEA-01 trial results showing ZIIHERA (zanidatamab) plus chemotherapy produced a statistically significant improvement in overall survival compared with trastuzumab plus chemotherapy in first-line treatment of HER2-positive gastroesophageal adenocarcinoma.
IDEAYA Biosciences (NASDAQ:IDYA) reported that an FDA Type C meeting provided guidance for the planned global randomized Phase 3 trial of IDE849, a DLL3-targeting TOP1 antibody-drug conjugate for extensive stage small cell lung cancer.
Alvotech (NASDAQ:ALVO) announced that the U.S. Food and Drug Administration accepted its Biologics License Application for AVT80, a proposed interchangeable biosimilar to Entyvio (vedolizumab) in prefilled syringe and autoinjector formats.
BioMarin (NASDAQ:BMRN) entered into binding global settlement terms with Ascendis Pharma A/S to resolve patent disputes involving Yuviwel, including a U.S. International Trade Commission investigation and litigation in multiple countries.
Amgen (NASDAQ:AMGN) reported Phase 3 VESALIUS-CV trial results showing Repatha reduced the risk of death by 20% among more than 12,000 high-risk adults without previous heart attack or stroke over a median 4.6-year follow-up.
Amarin (NASDAQ:AMRN) reported new post hoc REDUCE-IT Legacy analysis data showing that patients with high adherence to icosapent ethyl experienced an approximately 29%–30% relative reduction in the primary cardiovascular endpoint compared with placebo.
United Therapeutics (NASDAQ:UTHR) announced eight presentations at the 2026 European Society of Cardiology and European Respiratory Society congresses covering investigational therapies for pulmonary arterial hypertension and other lung diseases.
iBio (NASDAQ:IBIO) reported fiscal 2026 results as it advanced into clinical-stage development, with its Phase 1 trial of IBIO-600 progressing after 31 of 32 participants were dosed across four cohorts.
Eli Lilly (NYSE:LLY) received U.S. FDA approval for an expanded indication of Mounjaro (tirzepatide) to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes at high cardiovascular risk.
Quoin Pharmaceuticals (NASDAQ:QNRX) reported positive interim results from its Phase 2/3 CL-QRX003-004 study showing QRX003 4% lotion met its primary endpoint in the first six participants with Netherton Syndrome.
HUTCHMED (NASDAQ:HCM) received conditional approval from China’s National Medical Products Administration for ATLED® (fanregratinib, HMPL-453), an oral FGFR 1/2/3 inhibitor for certain adults with advanced intrahepatic cholangiocarcinoma.
AstraZeneca (NASDAQ:AZN) and Amgen (NASDAQ:AMGN) reported Phase III CROSSING trial results showing TEZSPIRE® (tezepelumab-ekko) achieved statistically significant improvements in eosinophilic esophagitis outcomes, with benefits maintained through week 52.
-640x360.webp&w=3840&q=75)
